441 related articles for article (PubMed ID: 24953948)
1. Identification and development of 2-methylimidazo[1,2-a]pyridine-3-carboxamides as Mycobacterium tuberculosis pantothenate synthetase inhibitors.
Samala G; Nallangi R; Devi PB; Saxena S; Yadav R; Sridevi JP; Yogeeswari P; Sriram D
Bioorg Med Chem; 2014 Aug; 22(15):4223-32. PubMed ID: 24953948
[TBL] [Abstract][Full Text] [Related]
2. Development of novel tetrahydrothieno[2,3-c]pyridine-3-carboxamide based Mycobacterium tuberculosis pantothenate synthetase inhibitors: molecular hybridization from known antimycobacterial leads.
Samala G; Devi PB; Nallangi R; Sridevi JP; Saxena S; Yogeeswari P; Sriram D
Bioorg Med Chem; 2014 Mar; 22(6):1938-47. PubMed ID: 24565972
[TBL] [Abstract][Full Text] [Related]
3. Development of 3-phenyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine derivatives as novel Mycobacterium tuberculosis pantothenate synthetase inhibitors.
Samala G; Devi PB; Nallangi R; Yogeeswari P; Sriram D
Eur J Med Chem; 2013 Nov; 69():356-64. PubMed ID: 24077526
[TBL] [Abstract][Full Text] [Related]
4. Structure-guided design of thiazolidine derivatives as Mycobacterium tuberculosis pantothenate synthetase inhibitors.
Devi PB; Samala G; Sridevi JP; Saxena S; Alvala M; Salina EG; Sriram D; Yogeeswari P
ChemMedChem; 2014 Nov; 9(11):2538-47. PubMed ID: 25155986
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of imidazo[2,1-b]thiazole and benzo[d]imidazo[2,1-b]thiazole derivatives as Mycobacterium tuberculosis pantothenate synthetase inhibitors.
Samala G; Devi PB; Saxena S; Meda N; Yogeeswari P; Sriram D
Bioorg Med Chem; 2016 Mar; 24(6):1298-307. PubMed ID: 26867485
[TBL] [Abstract][Full Text] [Related]
6. A discovery of novel Mycobacterium tuberculosis pantothenate synthetase inhibitors based on the molecular mechanism of actinomycin D inhibition.
Yang Y; Gao P; Liu Y; Ji X; Gan M; Guan Y; Hao X; Li Z; Xiao C
Bioorg Med Chem Lett; 2011 Jul; 21(13):3943-6. PubMed ID: 21641210
[TBL] [Abstract][Full Text] [Related]
7. Novel amide and sulphonamide derivatives of 6-(piperazin-1-yl)phenanthridine as potent Mycobacterium tuberculosis H37Rv inhibitors.
Naidu KM; Nagesh HN; Singh M; Sriram D; Yogeeswari P; Gowri Chandra Sekhar KV
Eur J Med Chem; 2015 Mar; 92():415-26. PubMed ID: 25590862
[TBL] [Abstract][Full Text] [Related]
8. Development of benzo[d]oxazol-2(3H)-ones derivatives as novel inhibitors of Mycobacterium tuberculosis InhA.
Pedgaonkar GS; Sridevi JP; Jeankumar VU; Saxena S; Devi PB; Renuka J; Yogeeswari P; Sriram D
Bioorg Med Chem; 2014 Nov; 22(21):6134-45. PubMed ID: 25282650
[TBL] [Abstract][Full Text] [Related]
9. Design, Synthesis, and in vitro antitubercular activity of 1,2,3-triazolyl-dihydroquinoline derivatives.
Banu S; Bollu R; Nagarapu L; Nanubolu JB; Yogeswari P; Sriram D; Gunda SK; Vardhan D
Chem Biol Drug Des; 2018 Jul; 92(1):1315-1323. PubMed ID: 29624868
[TBL] [Abstract][Full Text] [Related]
10. Design of Novel Mycobacterium tuberculosis Pantothenate Synthetase Inhibitors: Virtual Screening, Synthesis and In Vitro Biological Activities.
Devi PB; Jogula S; Reddy AP; Saxena S; Sridevi JP; Sriram D; Yogeeswari P
Mol Inform; 2015 Feb; 34(2-3):147-59. PubMed ID: 27490037
[TBL] [Abstract][Full Text] [Related]
11. Development of antimycobacterial tetrahydrothieno[2,3-c]pyridine-3-carboxamides and hexahydrocycloocta[b]thiophene-3-carboxamides: Molecular modification from known antimycobacterial lead.
Nallangi R; Samala G; Sridevi JP; Yogeeswari P; Sriram D
Eur J Med Chem; 2014 Apr; 76():110-7. PubMed ID: 24583350
[TBL] [Abstract][Full Text] [Related]
12. 5-tert-butyl-N-pyrazol-4-yl-4,5,6,7-tetrahydrobenzo[d]isoxazole-3-carboxamide derivatives as novel potent inhibitors of Mycobacterium tuberculosis pantothenate synthetase: initiating a quest for new antitubercular drugs.
Velaparthi S; Brunsteiner M; Uddin R; Wan B; Franzblau SG; Petukhov PA
J Med Chem; 2008 Apr; 51(7):1999-2002. PubMed ID: 18335974
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and structure activity relationship of imidazo[1,2-a]pyridine-8-carboxamides as a novel antimycobacterial lead series.
Ramachandran S; Panda M; Mukherjee K; Choudhury NR; Tantry SJ; Kedari CK; Ramachandran V; Sharma S; Ramya VK; Guptha S; Sambandamurthy VK
Bioorg Med Chem Lett; 2013 Sep; 23(17):4996-5001. PubMed ID: 23867166
[TBL] [Abstract][Full Text] [Related]
14. Design and development of novel Mycobacterium tuberculosis L-alanine dehydrogenase inhibitors.
Saxena S; Samala G; Sridevi JP; Devi PB; Yogeeswari P; Sriram D
Eur J Med Chem; 2015 Mar; 92():401-14. PubMed ID: 25585006
[TBL] [Abstract][Full Text] [Related]
15. Gyrase ATPase domain as an antitubercular drug discovery platform: structure-based design and lead optimization of nitrothiazolyl carboxamide analogues.
Jeankumar VU; Renuka J; Kotagiri S; Saxena S; Kakan SS; Sridevi JP; Yellanki S; Kulkarni P; Yogeeswari P; Sriram D
ChemMedChem; 2014 Aug; 9(8):1850-9. PubMed ID: 24962352
[TBL] [Abstract][Full Text] [Related]
16. Development of ssDNA aptamers as potent inhibitors of Mycobacterium tuberculosis acetohydroxyacid synthase.
Baig IA; Moon JY; Lee SC; Ryoo SW; Yoon MY
Biochim Biophys Acta; 2015 Oct; 1854(10 Pt A):1338-50. PubMed ID: 25988243
[TBL] [Abstract][Full Text] [Related]
17. Design and development of ((4-methoxyphenyl)carbamoyl) (5-(5-nitrothiophen-2-yl)-1,3,4-thiadiazol-2-yl)amide analogues as Mycobacterium tuberculosis ketol-acid reductoisomerase inhibitors.
Krishna VS; Zheng S; Rekha EM; Nallangi R; Sai Prasad DV; George SE; Guddat LW; Sriram D
Eur J Med Chem; 2020 May; 193():112178. PubMed ID: 32171154
[TBL] [Abstract][Full Text] [Related]
18. Functionalized 3-amino-imidazo[1,2-a]pyridines: a novel class of drug-like Mycobacterium tuberculosis glutamine synthetase inhibitors.
Odell LR; Nilsson MT; Gising J; Lagerlund O; Muthas D; Nordqvist A; Karlén A; Larhed M
Bioorg Med Chem Lett; 2009 Aug; 19(16):4790-3. PubMed ID: 19560924
[TBL] [Abstract][Full Text] [Related]
19. A Phenotypic Based Target Screening Approach Delivers New Antitubercular CTP Synthetase Inhibitors.
Esposito M; Szadocka S; Degiacomi G; Orena BS; Mori G; Piano V; Boldrin F; Zemanová J; Huszár S; Barros D; Ekins S; Lelièvre J; Manganelli R; Mattevi A; Pasca MR; Riccardi G; Ballell L; Mikušová K; Chiarelli LR
ACS Infect Dis; 2017 Jun; 3(6):428-437. PubMed ID: 28475832
[TBL] [Abstract][Full Text] [Related]
20. Discovery of novel lysine ɛ-aminotransferase inhibitors: An intriguing potential target for latent tuberculosis.
Devi PB; Sridevi JP; Kakan SS; Saxena S; Jeankumar VU; Soni V; Anantaraju HS; Yogeeswari P; Sriram D
Tuberculosis (Edinb); 2015 Dec; 95(6):786-794. PubMed ID: 26299907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
